John Torous News Today

This Medical News article is an interview with psychiatrist Vikram Patel, chair of the Department of Global Health and Social Medicine at Harvard Medical

This segment of Hemming’s ACP interview featured a discussion of a website used to assess digital applications for patients struggling with mental health issues.

New research highlights the potential of a smartphone-based tool that tracks vocal changes to identify depression and other mental health disorders.

High demand for AI training data may increase unethical practices in collecting patient data

The FDA's approval of Rejoyn, a prescription app designed to assist in treating major depression, marks a significant milestone in digital mental health care.

The US Food and Drug Administration has approved the first-ever prescription app for major depressive disorder.

Demand for mental health apps has soared in recent years but many fail to meet the quality threshold for issues such as clinical effectiveness, data privacy and security

The Rejoyn therapy app was approved by the FDA as add-on treatment for adults with depression who are already taking an antidepressant.

The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder.

Washington, Apr 4 (Prensa Latina) Rejoyn, the first digital prescription treatment against major depressive disorder, received the green light from the United States Food and Drug Administration; however, some experts remain skeptical about this initiative.